NASDAQ:AGTC - Applied Genetic Technologies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.17 -0.33 (-5.08 %) (As of 12/10/2018 04:00 PM ET)Previous Close$6.50Today's Range$6.1406 - $6.4752-Week Range$3.45 - $7.50Volume79,414 shsAverage Volume113,901 shsMarket Capitalization$117.85 millionP/E Ratio-5.23Dividend YieldN/ABeta2.03 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida. Receive AGTC News and Ratings via Email Sign-up to receive the latest news and ratings for AGTC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGTC Previous Symbol CUSIPN/A Webwww.agtc.com Phone386-462-2204 Debt Debt-to-Equity RatioN/A Current Ratio4.32 Quick Ratio4.32 Price-To-Earnings Trailing P/E Ratio-5.23 Forward P/E Ratio-4.94 P/E GrowthN/A Sales & Book Value Annual Sales$24.19 million Price / Sales4.62 Cash FlowN/A Price / Cash FlowN/A Book Value$5.48 per share Price / Book1.13 Profitability EPS (Most Recent Fiscal Year)($1.18) Net Income$-21,300,000.00 Net Margins-67.02% Return on Equity-18.97% Return on Assets-15.19% Miscellaneous Employees78 Outstanding Shares18,130,000Market Cap$117.85 million OptionableOptionable Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions What is Applied Genetic Technologies' stock symbol? Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC." How were Applied Genetic Technologies' earnings last quarter? Applied Genetic Technologies Corp (NASDAQ:AGTC) announced its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported $0.07 earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.50) by $0.57. The biotechnology company had revenue of $14.03 million for the quarter, compared to analysts' expectations of $2.90 million. Applied Genetic Technologies had a negative return on equity of 18.97% and a negative net margin of 67.02%. View Applied Genetic Technologies' Earnings History. When is Applied Genetic Technologies' next earnings date? Applied Genetic Technologies is scheduled to release their next quarterly earnings announcement on Friday, February 8th 2019. View Earnings Estimates for Applied Genetic Technologies. What price target have analysts set for AGTC? 5 brokerages have issued 1-year target prices for Applied Genetic Technologies' stock. Their predictions range from $5.00 to $9.00. On average, they expect Applied Genetic Technologies' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 13.5% from the stock's current price. View Analyst Price Targets for Applied Genetic Technologies. What is the consensus analysts' recommendation for Applied Genetic Technologies? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Applied Genetic Technologies. Has Applied Genetic Technologies been receiving favorable news coverage? Media stories about AGTC stock have trended very positive on Monday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Applied Genetic Technologies earned a news sentiment score of 3.9 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. Who are some of Applied Genetic Technologies' key competitors? Some companies that are related to Applied Genetic Technologies include Replimune Group (REPL), PDL BioPharma (PDLI), Mesoblast (MESO), Translate Bio (TBIO), Nightstar Therapeutics (NITE), CASI Pharmaceuticals (CASI), La Jolla Pharmaceutical (LJPC), Voyager Therapeutics (VYGR), Cellular Biomedicine Group (CBMG), MeiraGTx (MGTX), Krystal Biotech (KRYS), LogicBio Therapeutics (LOGC), Agenus (AGEN), Gamida Cell (GMDA) and Sutro Biopharma (STRO). Who are Applied Genetic Technologies' key executives? Applied Genetic Technologies' management team includes the folowing people: Ms. Susan B. Washer, Pres, CEO & Director (Age 57)Mr. William A. Sullivan, Chief Financial Officer (Age 47)Dr. Matthew Feinsod, Interim Chief Medical Officer (Age 47)Dr. Nicholas Muzyczka, Co-FounderDr. Barry J. Byrne, Co-Founder Who are Applied Genetic Technologies' major shareholders? Applied Genetic Technologies' stock is owned by many different of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (4.51%), Renaissance Technologies LLC (3.90%), Wells Fargo & Company MN (1.19%), Point72 Asset Management L.P. (0.93%), Man Group plc (0.72%) and Bridgeway Capital Management Inc. (0.70%). View Institutional Ownership Trends for Applied Genetic Technologies. Which major investors are selling Applied Genetic Technologies stock? AGTC stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Alambic Investment Management L.P., Point72 Asset Management L.P., Bridgeway Capital Management Inc. and ClariVest Asset Management LLC. View Insider Buying and Selling for Applied Genetic Technologies. Which major investors are buying Applied Genetic Technologies stock? AGTC stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Dimensional Fund Advisors LP and Renaissance Technologies LLC. View Insider Buying and Selling for Applied Genetic Technologies. How do I buy shares of Applied Genetic Technologies? Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Applied Genetic Technologies' stock price today? One share of AGTC stock can currently be purchased for approximately $6.17. How big of a company is Applied Genetic Technologies? Applied Genetic Technologies has a market capitalization of $117.85 million and generates $24.19 million in revenue each year. The biotechnology company earns $-21,300,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. Applied Genetic Technologies employs 78 workers across the globe. What is Applied Genetic Technologies' official website? The official website for Applied Genetic Technologies is http://www.agtc.com. How can I contact Applied Genetic Technologies? Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204. MarketBeat Community Rating for Applied Genetic Technologies (NASDAQ AGTC)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 319 (Vote Outperform)Underperform Votes: 192 (Vote Underperform)Total Votes: 511MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies and other stocks. Vote "Outperform" if you believe AGTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGTC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/10/2018 by MarketBeat.com StaffFeatured Article: What is a Tariff?